Please ensure Javascript is enabled for purposes of website accessibility

Why Akebia Therapeutics Stock Is Soaring Today

By Keith Speights – Aug 5, 2021 at 4:00PM

Key Points

  • Akebia met analysts' Q2 revenue estimate but posted a wider net loss than expected.
  • The financial results weren't the main focus for investors.
  • The main story for Akebia is the company's anticipated FDA approval of vadadustat.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked what they heard in the company's Q2 update.

What happened

Shares of Akebia Therapeutics (AKBA -2.07%) were soaring 13.5% as of 3:32 p.m. EDT on Thursday. The big jump came after the company provided its second-quarter financial and operational update. 

So what

Akebia reported Q2 revenue of $52.9 million. This result was down sharply from $90.1 million in the prior-year period due mainly to lower collaboration revenue but it was in line with the consensus estimate.

A person connected to a hemodialysis machine.

Image source: Getty Images.

The company posted a net loss of $83 million, or $0.51 per share. This reflected significant improvement from the year-ago period, although it was worse than analysts' average estimate of a net loss of $0.32 per share.

Akebia's financial results probably weren't the main reason behind the jump for the biotech stock today, though. Investors are likely more excited about the prospects for U.S. Food and Drug Administration (FDA) approval for vadadustat in treating anemia due to chronic kidney disease (CKD) in both adult patients on dialysis and not on dialysis.

The company's management didn't reveal any new information. However, executives seemed to be confident about the prospects for vadadustat to win FDA approval.

Now what

The FDA set a PDUFA date of March 29, 2022, to make a decision on vadadustat. In the meantime, Akebia will focus on marketing Auryxia for CKD patients on dialysis. The company thinks that it has enough cash to fund operations at least through the next 12 months and potentially well beyond then if vadadustat wins FDA approval.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akebia Therapeutics Stock Quote
Akebia Therapeutics
AKBA
$0.26 (-2.07%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.